Evidence map›Paper›PMID 39676133›Full record

ArticleAnnals of hematology2025

A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland.

Anna Anttalainen, Essi Havula, Kai Kysenius, Iiro Toppila, Tatu Miettinen, Mariann Lassenius, Raija Silvennoinen, Anu Partanen, Mervi Putkonen

Abstract read
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna AnttalainenMedaffcon Oy, Espoo, Finland.
Essi HavulaMedaffcon Oy, Espoo, Finland.
Kai KyseniusMedaffcon Oy, Espoo, Finland.
Iiro ToppilaMedaffcon Oy, Espoo, Finland.
Tatu MiettinenMedaffcon Oy, Espoo, Finland.
Mariann LasseniusMedaffcon Oy, Espoo, Finland.
Raija SilvennoinenDepartment of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Anu PartanenDepartment of Medicine, Kuopio University Hospital, Kuopio, Finland.
Mervi PutkonenDepartment of Hematology, Turku University Hospital, Turku, Finland. mervi.putkonen@tyks.fi.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infections are a clinically significant cause of mortality in multiple myeloma (MM) patients. The high number of infections in MM patients is due to the immunosuppressive effects of the disease itself as well as treatment-related immunosuppression. In this real-world evidence (RWE) study, we used several nationwide healthcare registries of Finland to investigate the effect of infection load on mortality in MM patients during 1997-2021. The highest number of infections was recorded during the first year after MM diagnosis. In patients who received allogenic or autologous stem cell transplantation (ASCT), the number of infections during the first two years post diagnosis was significantly higher than in those treated without ASCT. When compared to their age-, sex-, and region-matched controls, MM patients accrued more infections during the year prior to diagnosis. Intriguingly, patients under 70 years old had significantly more infections already 3 years before diagnosis when compared to their matched controls. Prior to MM diagnosis, the relative proportion of streptococcal septicaemia and pneumonia due to Streptococcus pneumoniae increased the most. Of note, even one recorded infection prior to diagnosis was associated with significantly shorter median overall survival. Importantly, Cox proportional hazard models show that recorded infections both before and after diagnosis increase the independent risk of mortality in MM patients.

Indexed as

InfectionsMultiple MyelomaAdultAgedFemaleFinlandHumansMaleMiddle AgedRegistriesSurvival RateAutologous stem cell transplant (ASCT)HematologyInfectionMultiple myelomaOncologyReal-world evidence (RWE)

Identifiers

PMID39676133
PMCPMC12053341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.